Eisai Taps Novartis Oncology Firepower For Lenvima
This article was originally published in PharmAsia News
Executive Summary
Following the recent approval of Lenvima for kidney cancer in the US, Eisai has allied with major oncology player Novartis to help drive sales of the product in this market.